Genitourinary Bacillus Calmette-Guerin Infection after BCG Intravesical Administration in a Patient under Hemodialysis — What Can We Do Better?
Open Access
- 1 January 2022
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Advances in Infectious Diseases
- Vol. 12 (03), 563-567
- https://doi.org/10.4236/aid.2022.123041
Abstract
A 74-year-old man with terminal chronic kidney disease, under hemodialysis and with residual diuresis, was admitted due to myalgia, arthralgia, fever and pyuria in the previous 10 days. The patient had a recent diagnosis of high-grade non-invasive bladder cancer and was doing weekly BCG intravesical administrations. The symptoms started three days before the fifth administration. He had done cefixime as an outpatient and started piperacillin-tazobactam on hospital admission, but the fever persisted, and there was no bacterial isolation in urine or blood culture. On the tenth and seventeenth day after the last BCG intravesical administration Mycobacterium bovis was still isolated in the urine culture. The diagnosis of BCGitis was made and treatment was started, with a good response. Forty days after the last administration and under treatment, the culture remained positive for Mycobacterium bovis in the urine. We raise the question about the safety of BCG administration in patients with residual diuresis.Keywords
This publication has 6 references indexed in Scilit:
- Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder CancerMedicine, 2015
- BCGitis: A rare complication after intravesical BCG therapyJornal Brasileiro de Pneumologia, 2015
- The management of BCG failure in non-muscle-invasive bladder cancer: an updateCanadian Urological Association Journal, 2013
- Bacillus Calmette–Guerin immunotherapy for urothelial carcinoma of the bladderImmunotherapy, 2009
- Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancerBJU International, 2002
- Systemic Bacillus Calmette-Guérin Infection, ‘BCGitis’, in Patients Treated by Intravesical Bacillus Calmette-Guérin Therapy for Bladder CancerEuropean Urology, 1989